Abstract
Here we found that the transcription repressor DREAM bound to the promoter of the gene encoding A20 to repress expression of this deubiquitinase that suppresses inflammatory NF-κB signaling. DREAM-deficient mice displayed persistent and unchecked A20 expression in response to endotoxin. DREAM functioned by transcriptionally repressing A20 through binding to downstream regulatory elements (DREs). In contrast, binding of the transcription factor USF1 to the DRE-associated E-box domain in the gene encoding A20 activated its expression in response to inflammatory stimuli. Our studies define the critical opposing functions of DREAM and USF1 in inhibiting and inducing A20 expression, respectively, and thereby the strength of NF-κB signaling. Targeting of DREAM to induce USF1-mediated A20 expression is therefore a potential anti-inflammatory strategy for the treatment of diseases associated with unconstrained NF-κB activity, such as acute lung injury.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Carrión, A.M., Link, W.A., Ledo, F., Mellstrom, B. & Naranjo, J.R. Dream is a Ca2+-regulated transcriptional repressor. Nature 398, 80–84 (1999).
Carrión, A.M., Mellstrom, B. & Naranjo, J.R. Protein kinase A-dependent derepression of the human prodynorphin gene via differential binding to an intragenic silencer element. Mol. Cell. Biol. 18, 6921–6929 (1998).
Ledo, F., Carrion, A.M., Link, W.A., Mellistrom, B. & Naranjo, J.R. DREAM-αCREM interaction via leucine-charged domains derepresses downstream regulatory element-dependent transcription. Mol. Cell. Biol. 20, 9120–9126 (2000).
Cheng, H.Y. et al. DREAM is a critical transcriptional repressor for pain modulation. Cell 108, 31–43 (2002).
Iadarola, M.J., Brady, L.S., Draisci, G. & Dubner, R. Enhancement of dynorphin gene expression in spinal cord following experimental inflammation: stimulus specificity, behavioral parameters and opioid receptor binding. Pain 35, 313–326 (1988).
Savignac, M. et al. Transcriptional repressor DREAM regulates T-lymphocyte proliferation and cytokine gene expression. EMBO J. 24, 3555–3564 (2005).
Savignac, M. et al. Increased B cell proliferation and reduced Ig production in DREAM transgenic mice. J. Immunol. 185, 7527–7536 (2010).
Amir-Zilberstein, L. & Dikstein, R. Interplay between E-box and NF-κB in regulation of A20 gene by DRB sensitivity-inducing factor (DSIF). J. Biol. Chem. 283, 1317–1323 (2008).
Hayden, M.S. & Ghosh, S. Shared principles of NF-κB signaling. Cell 132, 344–362 (2008).
Bonizzi, G. & Karin, M. The two NF-κB activation pathways and their role in innate and adaptive immunity. Trends Immunol. 25, 280–288 (2004).
Hoffmann, A. & Baltimore, D. Circuitry of nuclear factor κB signaling. Immunol. Rev. 210, 171–186 (2006).
Bair, A.M. et al. Ca2+ entry via TRPC channels is necessary for thrombin-induced NF-κB activation in endothelial cells through AMP-activated protein kinase and protein kinase Cδ. J. Biol. Chem. 284, 563–574 (2009).
Werner, S.L. et al. Encoding NF-κB temporal control in response to TNF: distinct roles for the negative regulators IκBα and A20. Genes Dev. 22, 2093–2101 (2008).
Opipari, A.W. Jr., Hu, H.M., Yabkowitz, R. & Dixit, V.M. The A20 zinc finger protein protects cells from tumor necrosis factor cytotoxicity. J. Biol. Chem. 267, 12424–12427 (1992).
Song, H.Y., Rothe, M. & Goeddel, D.V. The tumor necrosis factor-inducible zinc finger protein A20 interacts with TRAF1/TRAF2 and inhibits NF-κB activation. Proc. Natl. Acad. Sci. USA 93, 6721–6725 (1996).
Wertz, I.E. et al. De-ubiquitination and ubiquitin ligase domains of A20 downregulate NF-κB signalling. Nature 430, 694–699 (2004).
Boone, D.L. et al. The ubiquitin-modifying enzyme A20 is required for termination of Toll-like receptor responses. Nat. Immunol. 5, 1052–1060 (2004).
Coornaert, B., Carpentier, I. & Beyaert, R. A20:Central gatekeeper in inflammation and immunity. J. Biol. Chem. 284, 8217–8221 (2009).
Hymowitz, S.G. & Wertz, I.E. A20: from ubquitin editing to tumor suppression. Nat. Rev. Cancer 10, 332–341 (2010).
Harhaj, E.W. & Dixit, V.M. Regulation of NF-κB by deubiquitinases. Immunol. Rev. 246, 107–124 (2012).
Skaug, B. et al. Direct, noncatalytic mechanism of IKK inhibition by A20. Mol. Cell 44, 559–571 (2011).
Lee, E.G. et al. Failure to regulate TNF-induced NF-κB and cell death responses in A20-deficient mice. Science 289, 2350–2354 (2000).
Li, H.L. et al. Targeted cardiac overexpression of A20 improves left ventricular performance and reduces compensatory hypertrophy after myocardial infarction. Circulation 115, 1885–1894 (2007).
Wolfrum, S., Teupser, D., Tan, M., Chen, K.Y. & Breslow, J.L. The protective effect of A20 on atherosclerosis in apolipoprotein E-deficient mice is associated with reduced expression of NF-κB target genes. Proc. Natl. Acad. Sci. USA 104, 18601–18606 (2007).
Haies, D.M., Gil, J. & Weibel, E.R. Morphometric study of rat lung cells. I. Numerical and dimensional characteristics of parenchymal population. Am. Rev. Respir. Dis. 123, 533–541 (1981).
Zhao, Y.Y. et al. Endothelial cell-restricted disruption of FoxM1 impairs endothelial repair following LPS-induced vascular injury. J. Clin. Invest. 116, 2333–2343 (2006).
Deshmane, S.L., Kremlev, S., Amini, S. & Sawaya, B.E. Monocyte chemoattractant protein-1 (MCP-1): an overview. J. Interferon Cytokine Res. 29, 313–326 (2009).
Zhou, M.Y. et al. In vivo expression of neutrophil inhibitory factor via gene transfer prevents LPS-induced lung neutrophil infiltration and injury by β2 integrin-dependent mechanism. J. Clin. Invest. 101, 2427–2437 (1998).
Broman, M.T. et al. Cdc42 regulates adherens junction stability and endothelial permeability by inducing α-catenin interaction with the vascular endothelial cadherin complex. Circ. Res. 98, 73–80 (2006).
Sato, S. et al. Essential function for the kinase TAK1 in innate and adaptive immune responses. Nat. Immunol. 6, 1087–1095 (2005).
Ye, X. et al. Divergent roles of endothelial NF-κB in multiple organ injury and bacterial clearance in mouse models of sepsis. J. Exp. Med. 205, 1303–1315 (2008).
Ghosh, S. & Hayden, M.S. New regulators of NF-κB in inflammation. Nat. Rev Immunol. 8, 837–848 (2008).
Yin, X., Krikorian, P. & Logan, T. Induction of RIP-2 kinase by proinflammatory cytokines is mediated via NF-κB signaling pathways and involves a novel feed-forward regulatory mechanism. Mol. Cell. Biochem. 333, 251–259 (2010).
Sakurai, H. Targeting of TAK1 in inflammatory disorders and cancer. Trends Pharmacol. Sci. 33, 522–530 (2012).
Rey, S. et al. Synergistic effect of HIF-1α gene therapy and HIF-1-activated bone marrow-derived angiogenic cells in a mouse model of limb ischemia. Proc. Natl. Acad. Sci. USA 106, 20399–20404 (2009).
Hickey, M.J. et al. Inducible nitric oxide synthase (iNOS) in endotoxemia: chimeric mice reveal different cellular sources in various tissues. FASEB J. 16, 1141–1143 (2002).
Vogel, S.M. et al. Abrogation of thrombin-induced increase in pulmonary microvascular permeability in proteinase activated receptor-1 (PAR-1−/−) knockout mice. Physiol. Genomics 4, 137–145 (2000).
Tiruppathi, C. et al. Impairment of store-operated Ca2+ entry in TRPC4−/− mice interferes with increase in lung microvascular permeability. Circ. Res. 91, 70–76 (2002).
Wang, Y.L. et al. Innate immune function of the aherens junction protein p120-catenin in endothelial response to endotoxin. J. Immunol. 186, 3180–3187 (2011).
Rittirsch, D., Huber-Lang, M.S., Flierl, M.A. & Ward, P.A. Immuno design of experimental sepsis by cecal ligation and puncture. Nat. Protoc. 4, 31–36 (2009).
Paria, B.C. et al. Ca2+ influx-induced by PAR-1 activates a feed forward mechanism of TRPC1 expression via NF-κB activation in endothelial cells. J. Biol. Chem. 281, 20715–20727 (2006).
Gatta, R. & Mantovani, R. Single nucleosome ChIPs identify an extensive switch of acetyl marks on cell cycle promoters. Cell Cycle 9, 2149–2159 (2010).
Acknowledgements
We thank J.M. Penninger (Institute of Molecular Biotechnology of the Austrian Academy of Sciences) for DREAM-deficient mice, and Y.B. Wu for help with the isolation and culture of LECs. Supported by the US National Institutes of Health (P01 HL077806).
Author information
Authors and Affiliations
Contributions
C.T., D.S., J.W.C., A.M. and A.B.M. designed the research; C.T., D.S., D.-M.W., J.X., V.S., P.B.T., B.P.C., R.K.M., A.D., Z.Q., K.B., Y.-Y.Z. and S.M.V. did the experiments; C.T. analyzed data; and C.T. and A.B.M. wrote the manuscript.
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Integrated supplementary information
Supplementary Figure 1 Wild type (WT) bone marrow cells fail to induce lung vascular injury in Dream–/– mice following LPS challenge.
a, At 3 weeks following bone marrow cells transplantation, recipient mouse blood was collected from by tail nick. DNA was isolated using blood cells from a recipient female or male mouse. Polymerase chain reaction (PCR) for Sry gene (male specific) and autosomal gene Nme1 was performed to determine the reconstitution of bone marrow cells35. Representative PCR results are shown. Male-WT bone marrow (BM) cells transplanted recipient female Dream–/– mice were positive for Sry gene whereas female-WT bone marrow cells transplanted recipient male Dream–/– mice were negative for Sry gene. Positive and negative controls were included. b and c, WT, Dream–/–, or chimeric (WT-BM→ Dream–/–) mice (6 weeks after transplantation) were challenged with LPS (10 mg/kg, i.p.) and lungs were removed at the indicated times. Lung tissue homogenates were used for immunoblot to determine ICAM-1, A20, DREAM, and β-actin. Representative blots are shown in b. Immunoblots quantified with values normalized to β-actin are shown in c. N = 6 in each group. **P< 0.01; ***p<0.001, difference between Dream+/+ and WT-BM→ Dream–/– group (unpaired two-tailed Student's t-test). d, Cytokines (MCP-1, TNF, and IL-6) in BALF were measured after LPS challenge. N = 6 in each group; *p< 0.05, **p<0.01, ***p<0.001, difference between LPS-injected WT and Dream–/–- mice or WT and WT-BM→ Dream–/– mice (unpaired two-tailed Student's t-test). e, Cytokines (MCP-1, TNF, and IL-6) in serum were measured after LPS challenge. N = 6 in each group; *p< 0.05, **p<0.001, n.s. not significant, difference between LPS-injected WT and Dream–/– mice (unpaired two-tailed Student's t-test). f, MPO activity in BALF was measured after LPS challenge. N = 6 in each group; **p< 0.01, ***p<0.001, difference between LPS-injected WT and Dream–/– mice or WT and WT-BM→ Dream–/– mice (unpaired two-tailed Student's t-test). g, Survival of Dream+/+, Dream-/-, WT-BM→ Dream–/– mice after LPS challenge (10 mg/kg, i.p.). Age and weight matched mice were followed for 6 days after LPS administration. n = 8 in each group. **p< 0.01, vs. Dream+/+ mice using the log-rank test.
Supplementary Figure 2 LPS induces the mobilization of DREAM in BMDMs and analysis of the regulation of A20 transcription coordinated by DREAM and USF1.
a, WT-mice BMDMs were challenged with LPS (1 μg/ml) for different time intervals. After this treatment, cytosolic and nuclear fractions were prepared12 and used for immunoblot analysis to determine DREAM, β-actin (cytosolic marker), or MCM3 (nuclear marker). Data are from representative of two experiments. Values normalized to β-actin or MCM3 are shown in right panels. b, In basal condition, DREAM binding to DREs localized on A20 promoter represses A20 transcription. Inflammatory stimuli (e.g., LPS and TNF)-induced activation of protein kinase A (PKA) results in phosphorylation of nuclear CREM (cAMP-response element modulator)2,3. Interaction of phospho-CREM with DREAM uncouples DREAM from DREs resulting in USF1 binding to DRE-E-box motif, which activates A20 transcription. A20 transcription can be restored by the dephosphoryation of phospho-CREM.
Supplementary Figure 3 LPS induces c-Fos expression.
a, Dream+/+ and Dream–/– mice were challenged with LPS (10 mg/kg, i.p.) and lungs were removed at the indicated times as described in Fig. 1a. Lung tissue was used for Western blot analysis of c-Fos protein expression. n = 5 per time point in each group. **p< 0.01 (unpaired two-tailed Student's t-test), different from Dream+/+ mice. b, BMDMs in culture from Dream+/+ and Dream–/– mice exposed to LPS (100 ng/ml) for different time intervals were used for IB to determine expression of c-Fos. Data shown are representative of three or more experiments. Immunoblots were quantified (right panels). *p<0.05, **p<0.01(unpaired two-tailed Student's t-test); different from Dream+/+.
Supplementary Figure 4 DREAM regulates TAK1 and IKK signaling in BMDMs.
BMDMs in culture from Dream+/+ and Dream–/– mice were exposed to LPS (100 ng/ml) for different time intervals and then cell lysates were used for IB to determine activation of TAK1 (a) and IKK (b). Data shown are representative of three or more experiments. Immunoblots were quantified (right panels). *p<0.05, **p<0.01, ***p<0.001 (unpaired two-tailed Student's t-test);different from Dream+/+.
Supplementary Figure 5 DREAM regulates the transcription of NF-κB signaling components differently.
Dream+/+ or Dream–/– mice lung tissue (LT) mRNA levels of NF-κB signaling components (TRAF2, TRAF6, RIP1, RIP2, IKKγ (Ikbkg), NF-κB1, NF-κB2, RelB, and c-Rel) were determined by qPCR. n = 4 mice per group. Values reported are mean ± S.D. **p<0.01, ***p<0.001 (unpaired two-tailed Student's t-test, significantly different from Dream+/+ mice.
Supplementary Figure 6 Model for DREAM regulation of NF-κB signaling and lung inflammatory injury.
IκB kinase (IKKα/IKKβ/IKKγ) activation downstream of TNFR or TLR4 requires K63-linked polyubiquitylation of TRAFs, RIPs, and IKKγ proteins (polyubiquitylation not indicated in the model)19,20. K63-linked polyubiquitylation of these proteins recruits TAK1 to form functional signaling complex which activates IκB kinase and p38 MAPK19,20. Both IκB kinase and p38 MAPK activation amplifies inflammatory responses by inducing the production of inflammatory cytokines and expression of ICAM-1 in lungs. A20 de-ubiquitylates, K63-linked polyubiquitin chains on TRAFs, RIPs, and IKKγ proteins to inhibit IκB kinase and p38 MAPK. This mechanism prevented lung inflammation and injury. DREAM functions by binding to the A20 gene DRE elements thereby represses A20 transcription, and thereby prevents activation of NF-κB and p38 MAPK to prevent lung inflammatory injury.
Supplementary information
Supplementary Text and Figures
Supplementary Figures 1–6 (PDF 736 kb)
Rights and permissions
About this article
Cite this article
Tiruppathi, C., Soni, D., Wang, DM. et al. The transcription factor DREAM represses the deubiquitinase A20 and mediates inflammation. Nat Immunol 15, 239–247 (2014). https://doi.org/10.1038/ni.2823
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/ni.2823
This article is cited by
-
Ubiquitin ligase CHFR mediated degradation of VE-cadherin through ubiquitylation disrupts endothelial adherens junctions
Nature Communications (2023)
-
Fibroblast A20 governs fibrosis susceptibility and its repression by DREAM promotes fibrosis in multiple organs
Nature Communications (2022)
-
Itaconic acid exerts anti-inflammatory and antibacterial effects via promoting pentose phosphate pathway to produce ROS
Scientific Reports (2021)
-
A20: a master regulator of arthritis
Arthritis Research & Therapy (2020)
-
Transcriptome analysis of the response provided by Lasiopodomys mandarinus to severe hypoxia includes enhancing DNA repair and damage prevention
Frontiers in Zoology (2020)